Lipodystrophy Market Expected to rise, 2034 | Ionis Pharmaceuticals, Regeneron Pharmaceuticals, Boehringer Ingelheim, expected to drive market

Lipodystrophy Market Expected to rise, 2034 | Ionis Pharmaceuticals, Regeneron Pharmaceuticals, Boehringer Ingelheim, expected to drive market
Lipodystrophy Market 2034
The Lipodystrophy market growth is driven by factors like increase in the prevalence of Lipodystrophy, investments in research and development, entry of emerging therapies during the study period 2020-2034.

The Lipodystrophy market report also offers comprehensive insights into the Lipodystrophy market size, share, Lipodystrophy epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Lipodystrophy market size growth forward.

Some of the key highlights from the Lipodystrophy Market Insights Report:

  • Several key pharmaceutical companies, including Ionis Pharmaceuticals, Regeneron Pharmaceuticals, Boehringer Ingelheim, and others, are developing novel products to improve the Lipodystrophy treatment outlook.

  • In November 2024, Amryt Pharma initiated an open-label extension of the APG-20 study to assess the long-term safety and efficacy of daily subcutaneous metreleptin treatment in individuals with partial lipodystrophy. This Phase 3 study aims to continue evaluating metreleptin’s long-term impact on this patient population.

  • Lipodystrophy is a rare condition characterized by abnormal fat distribution in the body, which can lead to either fat loss (lipoatrophy) or fat accumulation in unusual areas (lipohypertrophy). According to DelveInsight’s 2023 estimates, there were around 3,077 prevalent cases of lipodystrophy across the 7MM, with the United States accounting for 35% of these cases.

  • In 2023, 93% of diagnosed lipodystrophy cases were partial lipodystrophy, which predominantly affects females. This is primarily due to familial partial lipodystrophy (FPL), a common type linked to genetic mutations in the LMNA or PPARG genes, which are more frequent in women. Additionally, around 30% of lipodystrophy cases in the United States were classified as congenital generalized lipodystrophy, a condition marked by near-total fat loss, resulting in visible muscle mass, severe insulin resistance, early-onset diabetes, hypertriglyceridemia, and non-alcoholic fatty liver disease (NAFLD).

  • The US FDA has approved two therapies for lipodystrophy: MYALEPT (metreleptin) and EGRIFTA/EGRIFTA SV (tesamorelin), produced by Amryt Pharma and Thera Technologies, respectively. The pipeline for lipodystrophy treatment is limited, with only a few companies advancing their candidates through clinical trials. Notable candidates include REGN4461 by Regeneron Pharmaceuticals, which is currently in Phase II. The rarity of the condition poses challenges for patient recruitment in clinical trials, slowing the development of new treatments.

  • The US holds the largest share of the lipodystrophy market, driven by the high prevalence of the condition and the availability of approved treatments. MYALEPT (metreleptin) by Amryt Pharma plays a significant role, with its leptin-based therapy generating substantial revenue.

  • As per DelveInsight analysis, the Lipodystrophy market is anticipated to witness growth at a considerable CAGR

Strategise your business goals by understanding market dynamics @ Lipodystrophy Market Landscape

Lipodystrophy Overview

Lipodystrophy is a rare condition characterized by abnormal fat distribution, either through fat loss (lipoatrophy) or fat buildup (lipohypertrophy). It can either be congenital (inherited) or develop later in life. This disorder often results in significant metabolic issues. Congenital forms include congenital generalized lipodystrophy (CGL), which causes extensive fat loss and metabolic problems like insulin resistance, and familial partial lipodystrophy (FPL), where fat is lost in certain areas and accumulates in others. Acquired lipodystrophy may develop later in life, sometimes linked to autoimmune diseases. Acquired generalized lipodystrophy (AGL) causes widespread fat loss, while acquired partial lipodystrophy (APL) leads to progressive fat loss in the upper body with accumulation in the lower body. HIV-associated lipodystrophy can occur as a side effect of antiretroviral treatment.

Symptoms of lipodystrophy include fat loss in areas like the face, arms, legs, and buttocks, abnormal fat buildup in the neck and trunk, and metabolic problems such as insulin resistance and diabetes.

Diagnosis typically involves a clinical assessment, metabolic tests, imaging techniques such as MRI or CT scans, and, in some cases, genetic testing or fat biopsies.

Do you know the treatment paradigms for different countries? Download our Lipodystrophy Market Sample Report

Lipodystrophy Epidemiology Insights

  • DelveInsight’s 2023 estimates suggest that there were around 3,077 prevalent cases of the rare disease lipodystrophy across the 7MM, with the United States representing 35% of these cases.

Lipodystrophy Epidemiology Segmentation

DelveInsight’s Lipodystrophy market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Lipodystrophy historical patient pools and forecasted Lipodystrophy patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Lipodystrophy Market report proffers epidemiological analysis for the study period 2020-34 in the 7MM segmented into:

  • Lipodystrophy Prevalence

  • Age-Specific Lipodystrophy Prevalence

  • Gender-Specific Lipodystrophy Prevalence

  • Diagnosed and Treatable Cases of Lipodystrophy

Visit for more @ Lipodystrophy Epidemiological Insights

Lipodystrophy Market Insights:

  • The US holds the largest share of the lipodystrophy market, due to the high prevalence of the condition and the presence of approved treatments. MYALEPT (metreleptin) by Amryt Pharma is a major contributor, with its leptin-based therapy generating significant revenue, around $880,000.

Lipodystrophy Market Outlook

The lipodystrophy treatment market is progressing, highlighting both existing and new therapies. In the United States, leading approved treatments such as MYALEPT (metreleptin) and EGRIFTA/EGRIFTA SV (tesamorelin) dominate the market, generating significant revenue.

Lipodystrophy Marketed Drugs

  • MYALEPT (metreleptin): Amryt Pharma

  • EGRIFTA/EGRIFTA SV (tesamorelin): Thera Technologies

Lipodystrophy Emerging Drugs

  • REGN4461: Regeneron Pharmaceuticals

  • Subcutaneous Metreleptin: Amryt Pharma

Lipodystrophy Key Companies

  • Ionis Pharmaceuticals, Regeneron Pharmaceuticals, Boehringer Ingelheim, and others

For more information, visit Lipodystrophy Market Analysis, Patient Pool, and Emerging Therapies

Scope of the Lipodystrophy Market Report:

  • 11 Years Forecast

  • 7MM Coverage

  • Descriptive overview of Lipodystrophy, causes, signs and symptoms, diagnosis, treatment

  • Comprehensive insight into Lipodystrophy epidemiology in the 7MM

  • Lipodystrophy marketed and emerging therapies

  • Lipodystrophy companies

  • Lipodystrophy market drivers and barriers

Table of Contents:

1 Lipodystrophy Market Key Comprehensive Insights

2 Lipodystrophy Market Report Introduction

3 Competitive Intelligence Analysis for Lipodystrophy

4 Lipodystrophy Market Analysis Overview at a Glance

5 Executive Summary of Lipodystrophy

6 Lipodystrophy Epidemiology and Market Methodology

7 Lipodystrophy Epidemiology and Patient Population

8 Lipodystrophy Patient Journey

9 Lipodystrophy Treatment Algorithm, Lipodystrophy Current Treatment, and Medical Practices

10 Key Endpoints in Lipodystrophy Clinical Trials

11 Lipodystrophy Marketed Therapies

12 Lipodystrophy Emerging Therapies

13 Lipodystrophy: 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Lipodystrophy

16 Lipodystrophy Market Key Opinion Leaders Reviews

18 Lipodystrophy Market Drivers

19 Lipodystrophy Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Lipodystrophy Epidemiology 2034

DelveInsight’s “Lipodystrophy – Epidemiology Forecast to 2034” report delivers an in-depth understanding of the disease, historical and forecasted Lipodystrophy epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Lipodystrophy Pipeline 2024

“Lipodystrophy Pipeline Insights, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Lipodystrophy market. A detailed picture of the Lipodystrophy pipeline landscape is provided, which includes the disease overview and Lipodystrophy treatment guidelines.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/